We have located links that may give you full text access.
CLINICAL TRIAL
CLINICAL TRIAL, PHASE I
CLINICAL TRIAL, PHASE II
JOURNAL ARTICLE
MULTICENTER STUDY
RESEARCH SUPPORT, NON-U.S. GOV'T
Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
Cancer Chemotherapy and Pharmacology 2001 August
Rituximab, a mouse-human chimeric anti-CD20 monoclonal antibody, induces apoptosis in B cell non-Hodgkin's lymphoma (B-NHL) cells, in addition to lysis by complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. A group of 12 patients with relapsed CD20+ B-NHL were enrolled in a phase I study; 4 received rituximab 250 mg/m2 and 8 375 mg/m2 once weekly for 4 weeks. Grade 1 or 2 infusion-related toxicity such as 'flu-like symptoms and skin reactions were observed. Of the 11 patients eligible for study enrollment, 2 achieved a complete response (CR) and 5 a partial response (PR). The T 1/2 of rituximab was 445+/-361 h, and serum rituximab levels were measurable at 3 months. Thereafter, 90 relapsed patients with indolent B-NHL or mantle cell lymphoma (MCL) were enrolled in a phase II study and received rituximab 375 mg/m2x4 weekly infusions. A central pathology review and an extramural review disclosed that 13 patients were ineligible for final analysis. Factors affecting response and progression-free survival (PFS) were analyzed in the remaining 77 patients. The overall response rate (ORR) in indolent B-NHL and MCL was 61% (37/ 61, 95% CI 47-73%) and 46% (6/13, 95% CI 19-75%), respectively. The median PFS time was 245 days in indolent B-NHL and 111 days in MCL patients. Multivariate analysis revealed that the ORR was affected by the number of prior regimens (P=0.018) and that the PFS was affected by the following three factors: disease type (P = 0.000), presence of extranodal lesions (P=0.001). and number of prior regimens (P=0.007). The PFS times of patients with higher serum rituximab concentrations at day 14 (> or =70 microg/ml) and at 3 months (> or =10 microg/ml) were significantly longer than those of patients with lower concentrations (P=0.006 and P=0.0001, respectively). In conclusion, rituximab is more effective in indolent B-NHL than in MCL. Several prognostic factors and serum rituximab concentrations are useful for predicting the therapeutic efficacy.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app